American Capital Ltd.  

(Public, NASDAQ:ACAS)   Watch this stock  
Find more results for ACAS
-0.04 (-0.28%)
Real-time:   3:23PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.08 - 14.29
52 week 13.59 - 16.24
Open 14.23
Vol / Avg. 648,290.00/1.65M
Mkt cap 3.83B
P/E 18.71
Div/yield     -
EPS 0.76
Shares 264.90M
Beta 1.33
Inst. own 70%
Feb 11, 2015
American Capital Ltd at Credit Suisse Group Financial Services Forum Add to calendar
Feb 11, 2015
American Capital Ltd at Sterne Agee Financial Institutions Investor Conference Add to calendar
Feb 9, 2015
Q4 2014 American Capital Ltd Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 2, 2014
American Capital Ltd at FBR Fall Investor Conference
Nov 6, 2014
Q3 2014 American Capital Ltd Earnings Call - Webcast
Nov 5, 2014
Q3 2014 American Capital Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 88.37% 37.78%
Operating margin 51.16% 47.64%
EBITD margin - 48.87%
Return on average assets 6.74% 2.99%
Return on average equity 8.51% 3.49%
Employees 256 -
CDP Score - -


United States - Map
+1-301-9516122 (Phone)
+1-301-6546714 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


American Capital, Ltd. (American Capital) is an equity firm and global asset manager. American Capital invests in private equity, private debt, private real estate securities and other investments, technology investments, special situation investments, alternative asset funds managed by the Company. The Company primarily invests in senior and mezzanine debt and equity in buyouts of private companies sponsored by the Company (One Stop Buyouts) or sponsored by other private equity funds (Private Equity Buyouts) and provide capital directly to early stage and mature private and small public companies. It refers to its investments in these companies as its private finance portfolio. In April 2014, the Company sold its portfolio company SPL Acquisition Corp to Shenzhen Hepalink Pharmaceutical Co., Ltd.

Officers and directors

Malon Wilkus Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John R. Erickson Chief Financial Officer, President - Structured Finance
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian S. Graff President - Private Finance
Age: 49
Bio & Compensation  - Reuters
Gordon J. O'Brien President - Specialty Finance and Operations
Age: 48
Bio & Compensation  - Reuters
Ira J. Wagner President - European Private Finance
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Samuel A. Flax Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Darin R. Winn Senior Vice President, Senior Managing Director
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Philip R. Harper Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Susan K. Nestegard Director
Age: 53
Bio & Compensation  - Reuters
Mary C. Baskin Independent Director
Age: 63
Bio & Compensation  - Reuters